NewsBenzingaReported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial Benzinga 2026.10.26 07:32 (GMT+0) Open on Benzinga Other news Goldman Sachs Maintains Buy on Allegion, Raises Price Target to $206 Goldman Sachs Maintains Neutral on Duolingo, Raises Price Target to $135 Goldman Sachs Maintains Neutral on Fiverr Intl, Lowers Price Target to $9 Goldman Sachs Maintains Buy on Peloton Interactive, Lowers Price Target to $6.5 Goldman Sachs Maintains Neutral on Six Flags Entertainment, Lowers Price Target to $6 Genmab Presents Updated Phase 2 Data For Petosemtamab Plus Pembrolizumab In First-Line PD-L1–Positive Recurrent/Metastatic Head And Neck Cancer, At ESMO Congress 2026
Genmab Presents Updated Phase 2 Data For Petosemtamab Plus Pembrolizumab In First-Line PD-L1–Positive Recurrent/Metastatic Head And Neck Cancer, At ESMO Congress 2026
